FDA Approves Hympavzi for Hemophilia Treatment, Offering Novel Approach to Bleeding Disorder Management
WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) has approved Hympavzi (marstacimab-hncq) for routine prophylaxis aimed at preventing or reducing bleeding episodes in patients aged 12 and older …
FDA Approves Hympavzi for Hemophilia Treatment, Offering Novel Approach to Bleeding Disorder Management Read More